Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [F]FDG PET/CT in Early Triple-Negative Breast Cancer.

(1) Background: triple-negative breast cancer (TNBC) remains a clinical and therapeutic challenge primarily affecting young women with poor prognosis. TNBC is currently treated as a single entity but presents a very diverse profile in terms of prognosis and response to treatment. Positron emission tomography/computed tomography (PET/CT) with F-fluorodeoxyglucose ([F]FDG) is gaining importance for the staging of breast cancers.

Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer.

Due to the heterogeneity of tumour mass segmentation methods and lack of consensus, our study evaluated the prognostic value of pretherapeutic positron emission tomography with fluorodeoxyglucose (FDG-PET) metabolic parameters using different segmentation methods in patients with localized anal squamous cell carcinoma (SCC). Eighty-one patients with FDG-PET before radiochemotherapy were retrospectively analyzed. Semiquantitative data were measured with three fixed thresholds (35%, 41% and 50% of Maximum Standardized Uptake Value (SUVmax)) and four segmentation methods based on iterative approaches (Black, Adaptive, Nestle and Fitting).

Dual time point [F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues.

Purpose: For differentiating tumor from inflammation and normal tissues, fluorodeoxyglucose ([F]FDG) dual time point PET could be helpful. Albeit [F]FLT is more specific for tumors than [F]FDG; we explored the role of dual time point [F]FLT-PET for discriminating benign from malignant tissues.

Methods: Before any treatment, 85 womens with de novo unifocal breast cancer underwent three PET acquisitions at 33.

Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors.

Purpose: The aim of this retrospective study was to determine, at baseline, the prognostic value of different FDG-PET/CT quantitative parameters in a homogenous Ewing Sarcoma Family of Tumors (ESFT) adult population, compared with clinically relevant prognostic factors.

Methods: Adult patients from 3 oncological centers, all with proved ESFT, were retrospectively included. Quantitative FDG-PET/CT parameters (SUV (maximum, peak and mean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the primary lesion of each patient were recorded before treatment, as well as usual clinical prognostic factors (stage of disease, location, tumor size, gender and age).

The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.

Purpose: Merkel cell carcinomas (MCC) are neuroendocrine skin tumours frequently responsible for lymph node recurrence and metastatic disease and for which optimal management remains to be defined. The objective of this study was to evaluate the impact of (18)F-fluorodeoxyglucose ((18)F-FDG)-PET/computed tomography (CT) on the staging and treatment of MCC patients.

Materials And Methods: Twenty-three patients with a histologic diagnosis of MCC explored by (18)F-FDG-PET/CT between 2004 and 2012 were retrospectively included in the study.

Unusual uptake of 18FDG by a hepatic adenoma.

Hepatic adenoma is a rare, benign tumor (with potential for malignant degeneration) and its diagnosis is difficult because its presentation is highly variable in medical imaging, particularly with MRI. In such cases, the use of a hepatic biopsy is usually recommended. (18)FDG-PET/CT provides a very significant predictive value for malignant hepatic lesions.

Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy.

Background: Peritoneal carcinomatosis (PC) is associated with a very poor prognosis. Complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy has been shown to improve survival rates of PC. However, this treatment is beneficial for patients if the complete cytoreductive surgery is macroscopically completed before implementing hyperthermic intraperitoneal chemotherapy.

Uncommon breast tumor attenuation artifact on radionuclide ventriculography.

A 39-year-old woman with locally advanced left breast cancer (T4 N0 M0) underwent equilibrium radionuclide ventriculography for baseline assessment of left ventricular function before neoadjuvant chemotherapy. The left ventricular ejection fraction was 76% at 75 beats per minute, without localized wall motion abnormality. In the best septal left anterior oblique projection, a large photopenic "halo" surrounded the cardiac chambers, mimicking a pericardial effusion.